Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody

A method for predicting maintenance of response to IL-23 antibody therapy and treating a patient having psoriasis, the method comprising:

• a. administering subcutaneously an IL-23 antibody comprising a heavy chain variable region amino acid sequence of SEQ ID NO:7 and a light chain variable region amino acid sequence of SEQ ID NO:8 to the patient in an initial dose, 4 weeks after the initial dose and every 8 weeks after the dose at 4 weeks at a dose of 100 mg, wherein the patient is a responder to the IL-23 antibody and is identified as having a PASI90, PASI100 or IGA 0 or 1 score;
• b. obtaining or having obtained a biological sample from the patient;
• c. measuring or having measured at baseline or at any point during treatment at least one indicator from the patient or the biological sample selected from the group consisting of clinical parameters comprising duration of disease, BMI and/or IGA score;
• and PASI, a pharmacokinetic marker comprising blood concentration of the IL-23 antibody, and serum protein biomarkers comprising IL17F and MIP1β, before and during treatment with the IL-23 antibody;
• d. generating a predictive patient profile based on the measured indicator;
• and
• e. administering the maintenance therapy of the IL-23 antibody according to the predictive patient profile, wherein the maintenance therapy is administered at a dosing interval selected from the group consisting of greater than every 8 weeks, every 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, and 48 weeks.